COVID-19 - April 14, 2021
Johnson & Johnson’s vaccine temporarily paused
The company delays EU vaccine deliveries as US pauses use over blood clots. Johnson & Johnson is to pause deliveries of its single-shot COVID-19 vaccine in Europe pending an investigation of rare blood clot cases that have halted rollout in the US, it announced. “We have been reviewing these cases with European health authorities,” the […]
COVID-19 - March 12, 2021
Johnson & Johnson’s vaccine granted conditional marketing authorization in the EU
The European Commission has granted a Conditional Marketing Authorization for the company’s single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The CMA follows a Positive Opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The CMA is valid in all 27 member states […]
COVID-19 - February 17, 2021
Johnson & Johnson submits European cMAA
Johnson & Johnson has announced that Janssen-Cilag International has submitted a conditional Marketing Authorization Application (cMAA) to the European Medicines Agency (EMA) seeking authorization for its investigational single-dose Janssen COVID-19 vaccine candidate. The submission is based on efficacy and safety data from the Phase 3 ENSEMBLE clinical trial. Ready to begin distributing in Q2 2021 […]
Acquisition - August 12, 2015
Alligator Bioscience in billion-dollar business deal
Janssen Biotech, one of the Janssen pharmaceutical companies of Johnson & Johnson has entered an exclusive, worldwide license agreement with Alligator Bioscience AB for ADC-1013, an immuno-oncology agent currently in Phase 1 clinical studies. Under terms of the agreement, Janssen will attain rights to develop and commercialize ADC-1013, an agonistic fully human monoclonal antibody. ADC-1013 targets […]
